Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda, Teva to Commercialize Teva’s Parkinson’s Disease Treatment Rasagiline in Japan
April 30, 2014
-
ACADEMIA Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
-
REGULATORY MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
-
REGULATORY Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
-
BUSINESS MTPC Names Masayuki Mitsuka as New President
April 24, 2014
-
BUSINESS Astellas Aims to Dominate SGLT-2 Inhibitor Market with Suglat
April 23, 2014
-
BUSINESS Lilly Japan Starts PIII Study of Tadalafil for DMD Treatment
April 22, 2014
-
REGULATORY MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
April 21, 2014
-
REGULATORY New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn
April 18, 2014
-
REGULATORY Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear
April 18, 2014
-
BUSINESS Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
-
REGULATORY Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
April 17, 2014
-
BUSINESS Metal Found in Voltaren Product Again: Novartis
April 17, 2014
-
ORGANIZATION Funding for Investigator-Led Studies Should Be Based on Contracts: EFPIA Japan
April 16, 2014
-
BUSINESS FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
-
BUSINESS Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
-
ACADEMIA Public Hospitals Seeking to Avert Penalty Fee Cuts for Low Price Settlements
April 14, 2014
-
BUSINESS 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
-
REGULATORY Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
April 10, 2014
-
BUSINESS Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
April 9, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…